Baidu
map

雌性激素有望拯救失血过多患者

2015-11-11 桃子 煎蛋网

阿拉巴马大学伯明翰分校的研究人员们发现雌性激素或许能拯救失血达60%的受伤士兵和失血患者,这是一项突破性的发现。阿拉巴马大学伯明翰分校外科研究中心的主任Irshan Chaudry花了十九年时间来做这个敏感性研究,最近美国国防部与Chaudry签订价值一千万美元的合同,准备开始对合成雌激素(也被称作E2)进行人体临床安全试验。战场上士兵死亡的主要原因是伤口失血过多无法得到处理,而在许多情况下本来可

阿拉巴马大学伯明翰分校的研究人员们发现雌性激素或许能拯救失血达60%的受伤士兵和失血患者,这是一项突破性的发现。阿拉巴马大学伯明翰分校外科研究中心的主任Irshan Chaudry花了十九年时间来做这个敏感性研究,最近美国国防部与Chaudry签订价值一千万美元的合同,准备开始对合成雌激素(也被称作E2)进行人体临床安全试验。

战场上士兵死亡的主要原因是伤口失血过多无法得到处理,而在许多情况下本来可以避免这样的事情。事实上,在2001-2011年期间,美国死在战斗中的士兵百分之八十死于可预防的失血和败血症。通常情况下,士兵受伤时身处的位置使得他们无法被迅速送往战地医院,导致医护人员治疗他们的时间大大减少。  Chaudry表示:“黄金处理时期是受伤后的一小时内。耽误的时间越长,影响越严重。”而处理的目的是为了确保士兵有命撑到战地医院。

一个人或者动物失血的时候,他们纤细的血管会崩溃,导致组织缺氧。如果这种情况没有得到改善,那么细胞就会逐渐死亡,器官罢工最终导致人或者动物丧生。Chaudry说:“我们能做的只有防止这种微循环减少。人体失血后就像一片沼泽地,我们要找的就是能把它变成小溪的东西。”  是什么令雌激素成为能拯救生命的荷尔蒙?令人惊讶的是,不论男女,人体每个细胞的线粒体中都有雌激素受体。Chaudry表示:“当雌激素受体被激活时,它们会产生更多ATP(细胞内的‘能量货币’)。而我们因受伤而失血时,细胞产生的ATP就会减少。”

1997年,Chaudry和他的合作者Rene Zellweger偶然之下发现了雌激素能增强免疫力和心血管功能。当时他们正在利用小白鼠来研究创伤出血患者遭受的感染症,由于雌性小白鼠体内的激素波动过大,因此Zellweger打算采用雄性小白鼠进行研究,但供应商意外给他们送来了雌性小白鼠。Chaudry将错就错地进行研究,结果他们发现雌性小白鼠对抗感染(这里指败血症)的能力比Chaudry预料中的更强。

Chaudry在兴奋之下订购了更多雌性小白鼠并重复了这一实验。第二次,实验失败了。他思索之后才意识到两批小白鼠处于不同阶段,第一批对抗感染能力强的雌性小白鼠在做实验时正好处于生理周期,而它们排卵之前体内的雌激素含量达到巅峰。

接下来,他们在失血的病人身上测试E2,发现E2能显着提高失血量高达百分之六十的病人的心血管和肝脏功能;而其中的原理在于它能扩张血管,让组织和血管之间的液体能更加有效地流动。它还能减少病人体内的炎性细胞因子,将病人的死亡或器官衰竭时间延缓3个小时。  2005年,美国国防部高级研究计划局(DARPA)举办一场竞赛,希望能找到能让士兵在严重失血的情况下多活3个小时的方法。Chaudry和他的研究小组站了出来。他们利用环糊精将E2微胶囊化,以便让它更溶于水。

从那以后,Chaudry的合成雌激素在DARPA的帮助下变身成为EE-3-SO4(ethinyl estradiol-3-sulfate)。一剂这样的药物能将老鼠和马的死亡延缓6个小时。Chaudry说:“人们遭受外伤后会出现水肿,因此如果我们能够将引起水肿的液体引回血液循环中,那么我们就能将病人或动物的身体维持在允许性低血压状态,足以维持他们的生命。”

与此同时,EE-3-SO4也可能对脑外伤患者有效。在研究中,雌激素还能减少水肿,增加大脑血流量并减少死亡的脑细胞。但以上两种雌激素的变异体也许都能运用到无法立即到达医院的普通人身上。

Chaudry最近正在等待FDA的认可,他有信心在一年内得到FDA批准,在一年内开始人体试验。他希望最后所有的急救车上都能携带雌激素,毕竟有备无患。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (25)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1818981, encodeId=88001818981f1, content=<a href='/topic/show?id=ecd698e5447' target=_blank style='color:#2F92EE;'>#雌性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98754, encryptionId=ecd698e5447, topicName=雌性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Nov 21 03:15:00 CST 2015, time=2015-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81984, encodeId=6b2881984af, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81983, encodeId=375b8198397, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81985, encodeId=e9c7819852f, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81986, encodeId=b08e81986a8, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81987, encodeId=60c68198e4e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81990, encodeId=967081990bd, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81992, encodeId=e33e8199211, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81991, encodeId=da658199174, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81988, encodeId=dfdb8198842, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

相关资讯

JCEM:雌激素诱导甲状腺乳头状癌细胞的自噬

甲状腺乳头状癌(PTC)的发生率在性别中的比例是女:男(1:3),关于性别差异的风险因素知之甚少。越来越多的研究认为雌激素在甲状腺肿瘤的发生中起重要作用,但是相关的机制并不清楚。近来有研究发现雌激素受体α(ER-α)可通过刺激活性氧的生成和胞外信号调节激酶诱导PTC的自噬。 研究者分析了ER-α在PTC患者甲状腺组织中的表达。通过化学和基因技术抑制PTC细胞自噬,检测PTC细胞的活力、增殖和

PNAS:颠覆 雌激素在宫颈癌癌中的作用

科学家们一直认为雌激素是宫颈癌生长的主要驱动因子。但一项最新研究表明,雌激素受体在宫颈癌细胞中几乎全部消失。相关论文发表在近期的美国国家科学院院刊PNAS杂志上。宫颈癌是女性中的第二大癌症,在发展中国家尤其常见,因为在那里早期筛查还不普遍。人们发现,几乎所有宫颈癌都是人乳头瘤病毒(HPV)感染引起的。研究人员对SUCCEED项目(Study to Understand Cervical Cance

Diabetes Care:雌激素会加剧糖尿病患者痴呆的发生

老年女性,雌激素水平越高,会加速因糖尿病导致的认知障碍。研究者进行了一项研究探究2型糖尿病患者中,对绝经后妇女进行激素替代治疗能都对糖尿病相关认知障碍产生影响。研究者将研究对象随机分为激素治疗组:0.625 mg/day结合雌激素 ±2.5 mg/day醋酸甲羟孕酮,以及安慰剂对照组(4.7-5.9 年)。该研究共纳入了7,233名女性,年龄 65-80 岁,根据2型糖尿病情况进行分类,并随访可能

Cell Stem Cell:为何从古至今女人都长寿?

人类中的超级百岁老人(即年龄超过110岁的人)至少都会有一个共同点,即超过95%的百岁老人都是女性,科学家们通过长期研究观察当人们衰老时不同性别之间个体的差异,但研究者目前并不清楚为何女性会活的更久一些。近日,刊登在国际杂志Cell Stem Cell上的一篇研究报道中,来自斯坦福大学的研究人员通过对干细胞的行为和性别差异进行研究,揭示了男性和女性随着机体老化而表现出的再生能力下降的差异,相关研究

Analyt Chim Acta:新技术高效检测雌激素含量

近日,一项发表于国际杂志Analytica Chimica Acta上的研究论文中,来自德州大学等处的研究人员通过研究开发了一种新方法,其可以帮助检测较少量样本中雌激素的含量,或将潜在改善癌症和其它疾病的检测方法。 我们都知道,雌激素在人体中发挥着重要的作用,而其也和肿瘤生长及阿尔兹海默氏症患者大脑中神经元的缺失等直接相关,但是在血液及其它体液中检测微量的雌激素非常困难,尤其是实验室有限的条

Diabetologia:GLP-1联合雌激素,可以阻止胰岛B细胞功能衰竭

之前有研究证明,雌激素有明显改善B细胞功能,降低血糖的作用。因此,近来开始研发GLP-1—雌激素结合物来治疗T2DM,此结合物可以将雌激素特异性的送至表达GLP-1受体的细胞,通过雌激素增加GLP-1对胰岛B细胞的保护作用。最近一篇研究就,比较了GLP-1和GLP-1—雌激素结合物在糖毒性环境中对胰岛B细胞的保护作用。研究中随机选取两组新西兰肥胖(NZO)小鼠,分别给予每日GLP-1和GLP-1—

Baidu
map
Baidu
map
Baidu
map